August 17, 2016

Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study demonstrates that CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. Our approach expands the spectrum of antigens available for redirected T-cell therapy against solid malignancies and offers a promising new avenue for liver cancer immunotherapy. Clin Cancer Res; 23(2); 478-88. ©2016 AACR.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Liu et al. (Wed,) studied this question.

synapsesocial.com/papers/69dd3fd68557d5ab8f40c438 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-16-1203

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevance1995 · 474 citations
2Serum tumor markers.2003 · 253 citations
3Production of Human Monoclonal Antibodies against FcεRIα by a Method Combining<i>in Vitro</i>Immunization with Phage Display2009 · 8 citations
4Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T2015 · 224 citations
5A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer2006 · 1,241 citations

Preguntar a la IA

Me gusta

Guardar